Ventus Therapeutics

Overview

Ventus Therapeutics is a drug discovery company focused on developing novel small molecule therapeutics targeting innate immunity pathways, particularly the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and gasdermin proteins. The company's innovative approach to modulating pyroptosis and inflammatory cell death positions it uniquely in the neurodegenerative disease space.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2018 |
| Headquarters | Cambridge, Massachusetts, USA |
| CEO | Dr. Juan Andres |
| Funding | Series B ($70M, 2023) |
| Focus | NLRP3 and gasdermin inhibitors |
| Stage | Preclinical |

Founding and Scientific Foundation

Ventus Therapeutics was founded based on research from leading academic institutions:

• Scientific founders: Dr. Thirumala-Devi Kanneganti (St. Jude Children's Research Hospital), Dr. Russell Vance (UC Berkeley)
• Research focus: Gasdermin biology and pyroptosis mechanisms
• Approach: Structure-based drug design targeting protein-protein interactions

The company's platform leverages cryo-EM structures of NLRP3 and gasdermins to design highly selective inhibitors.

Science and Technology

Dual-Target Platform

Ventus's platform targets two critical nodes in the inflammatory cascade:

NLRP3 inhibitors: Block inflammasome assembly and caspase-1 activation

Gasdermin inhibitors: Block pore formation by gasdermin D and related proteins

This dual approach provides broader anti-inflammatory effects than single-target approaches.

...

Overview

Ventus Therapeutics is a drug discovery company focused on developing novel small molecule therapeutics targeting innate immunity pathways, particularly the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and gasdermin proteins. The company's innovative approach to modulating pyroptosis and inflammatory cell death positions it uniquely in the neurodegenerative disease space.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2018 |
| Headquarters | Cambridge, Massachusetts, USA |
| CEO | Dr. Juan Andres |
| Funding | Series B ($70M, 2023) |
| Focus | NLRP3 and gasdermin inhibitors |
| Stage | Preclinical |

Founding and Scientific Foundation

Ventus Therapeutics was founded based on research from leading academic institutions:

• Scientific founders: Dr. Thirumala-Devi Kanneganti (St. Jude Children's Research Hospital), Dr. Russell Vance (UC Berkeley)
• Research focus: Gasdermin biology and pyroptosis mechanisms
• Approach: Structure-based drug design targeting protein-protein interactions

The company's platform leverages cryo-EM structures of NLRP3 and gasdermins to design highly selective inhibitors.

Science and Technology

Dual-Target Platform

Ventus's platform targets two critical nodes in the inflammatory cascade:

NLRP3 inhibitors: Block inflammasome assembly and caspase-1 activation

Gasdermin inhibitors: Block pore formation by gasdermin D and related proteins

This dual approach provides broader anti-inflammatory effects than single-target approaches.

Mechanism in Parkinson's Disease

In Parkinson's disease, both NLRP3 activation and gasdermin-mediated pyroptosis contribute to dopaminergic neuron death:

Alpha-synuclein aggregation → Microglial NLRP3 activation → Caspase-1 activation
↓
Gasdermin D cleavage
↓
Pyroptotic cell death
↓
Dopaminergic neuron loss

Ventus's inhibitors block this pathway at multiple points, potentially providing enhanced neuroprotection.

Pipeline

Programs

| Program | Target | Indication | Stage | Status |
|---------|--------|------------|-------|--------|
| VTS-101 | NLRP3 | Parkinson's disease | Preclinical | Lead optimization |
| VTS-202 | Gasdermin D | Neurodegeneration | Discovery | Hit-to-lead |
| VTS-303 | NLRP3/Gasdermin | Inflammatory diseases | Discovery | Early stage |

VTS-101 (Parkinson's Disease)

VTS-101 is Ventus's lead program for Parkinson's disease:

• Mechanism: Direct NLRP3 inhibition (NACHT domain binding)
• Selectivity: >100-fold over related NLRs
• BBB penetration: Designed for CNS exposure; brain-to-plasma ratio >0.3
• Pharmacokinetics: Once-daily oral dosing potential

Preclinical data in 6-OHDA rat model showed:

• Reduced dopaminergic neuron loss in substantia nigra
• Decreased IL-1β and IL-18 in CSF
• Improved behavioral outcomes on cylinder test
• No signs of immunosuppression at effective doses

VTS-202 (Gasdermin Inhibitor)

VTS-202 targets gasdermin D, the effector protein of pyroptosis:

• Mechanism: Prevents gasdermin D N-terminal domain oligomerization
• Selectivity: Selective for GSDMD over GSDMA, GSDMB, GSDMC
• Rationale: Blocks downstream of NLRP3/caspase-1

This approach may provide benefit even when NLRP3 is partially active.

Funding and Partnerships

| Round | Amount | Year | Investors |
|-------|--------|------|-----------|
| Series A | $25M | 2019 | Versant Ventures, Third Rock |
| Series B | $70M | 2023 | Google Ventures, Andreessen Horowitz, ARCH Venture |

Academic Collaborations

• Harvard Medical School: Dr. Hao Wu - Inflammasome structural biology
• University of Michigan: Dr. Katherine Fitzgerald - Innate immunity

Competitive Advantages

Structural insights: Cryo-EM structures of NLRP3-inhibitor complexes

Dual-target approach: NLRP3 + gasdermin inhibitors

BBB optimization: Dedicated CNS chemistry platform

Biomarker strategy: Development of NLRP3 activation biomarkers

Market Opportunity

The Parkinson's disease neuroinflammation market represents a significant opportunity:

| Parameter | Value |
|-----------|-------|
| Global PD patients | ~10 million |
| Target population | Early-to-mid stage patients with inflammation biomarkers |
| Market potential | $3-7B annually |
| Development timeline | 4-6 years to potential approval |

Competitive Landscape

Ventus competes with several companies in the NLRP3 space, but its gasdermin program provides a differentiated approach:

| Company | Focus | Differentiation |
|---------|-------|-----------------|
| Ventus | NLRP3 + Gasdermin | Dual mechanism |
| Olacteant | NLRP3 (Dapansutrile) | Clinical data |
| NodThera | NLRP3 | CNS expertise |
| IFM/BMS | NLRP3 | Big pharma resources |
| Novartis | NLRP3 (DFV890) | Phase 1 data |

Development Timeline

gantt
title Ventus Therapeutics PD Program
dateFormat YYYY
axisFormat %Y

section VTS-101
Lead optimization :active, 2023, 2025
IND-enabling :2025, 2026
Phase 1 :2026, 2027
Phase 2 :2027, 2029

section VTS-202
Hit-to-lead :active, 2024, 2025
Lead optimization :2025, 2026
IND-enabling :2026, 2027

References

[Ventus Therapeutics Website](https://www.ventustherapeutics.com)

[Fan Z et al., MCC950 neuroprotection in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35687654/)

See Also

• [NLRP3 Inflammasome Inhibitors for Parkinson's Disease](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons)
• [Pyroptosis Inhibition Therapy](/therapeutics/pyroptosis-inhibition-therapy)
• [NodThera Ltd.](/companies/nodthera)
• [IFM Therapeutics](/companies/ifm-therapeutics)
• [NLRP3 Inhibitors Investment Landscape](/investment/nlrp3-inflammasome)